Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type, I7 b: h( q, w6 H% B% d; s
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 - Q$ a5 c8 t& C$ N" @* ~
+ Author Affiliations
; R) ^- R) k: c. B) H5 B ^2 W
9 `3 `$ R" \/ W- ^0 K! N2 u8 I8 I1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
1 K2 w9 V) P+ Z5 r: Y5 O0 }2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 k9 u0 k4 Y% Q! Y" ]# a9 h$ R
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
6 R0 y. z% Q: S+ c" s; \% y4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 3 r1 m. a3 d. q4 S( C
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
. N/ o1 X) c6 s$ H6 `6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
r" [& t2 Y# t* _) b {7Kinki University School of Medicine, Osaka 589-8511, Japan
% i" _/ ?# M. y: c" r, G- Z8Izumi Municipal Hospital, Osaka 594-0071, Japan & ~3 a# x r S- |% i$ }! C3 _
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 9 l. R0 U5 j8 ]5 t* ]8 ?
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ; k8 z: D* }# s2 K
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
J0 I0 B& [, [/ m, m6 D: P) {2 J" l5 f9 p* W
|